• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腔积液中的纤溶和炎症过程。

Fibrinolytic and inflammatory processes in pleural effusions.

作者信息

Philip-Joët F, Alessi M C, Philip-Joët C, Aillaud M, Barriere J R, Arnaud A, Juhan-Vague I

机构信息

Service de Pneumologie-Allergologie, CHU Nord, Marseille, France.

出版信息

Eur Respir J. 1995 Aug;8(8):1352-6. doi: 10.1183/09031936.95.08081352.

DOI:10.1183/09031936.95.08081352
PMID:7489803
Abstract

This study was designed to evaluate major fibrinolytic parameters in relation to parameters of inflammation associated with different kinds of pleural effusion. Sixty patients with pleural effusion were studied. The underlying aetiology was empyema in 10 cases, tuberculosis in 9, cancer in 31, cardiac failure in 7, and undetermined in 3. Plasminogen, plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2), tissue type plasminogen activator (t-PA), urokinase (u-PA) and D-dimers (D-D) were quantified in plasma samples and pleural effusion specimens. These data were then correlated with inflammatory or infectious parameters, i.e. fibrinogen, von Willebrand factor (vWF), erythrocyte sedimentation rate (ESR), protein concentration, and white blood cell count. D-D levels were higher in pleural fluid than in plasma. D-D levels were not correlated with either plasminogen activator or plasminogen activator inhibitor levels, suggesting the presence of other fibrinolytic pathways. PAI levels (PAI activity, PAI-1 antigenicity, PAI-2 antigenicity) and vWF levels were significantly higher in patients with tuberculosis and empyema than in patients with cancer or cardiac failure. Regression analysis between inflammatory and fibrinolytic parameters showed that pleural PAI levels were significantly correlated with pleural neutrophil count, vWF levels, and plasma fibrinogen levels. D-D levels were correlated with blood ESR. No significant difference in pleural t-PA, u-PA and D-D levels was observed between aetiologies. The highest pleural t-PA and u-PA values were noted in patients with cancer, especially lymphoma. Plasma t-PA levels were higher inpatients with pleural effusion secondary to congestive heart failure, but this difference did not reach statistical significance.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究旨在评估与不同类型胸腔积液相关的炎症参数有关的主要纤溶参数。对60例胸腔积液患者进行了研究。潜在病因分别为:脓胸10例,结核9例,癌症31例,心力衰竭7例,病因不明3例。对血浆样本和胸腔积液标本中的纤溶酶原、纤溶酶原激活物抑制剂1(PAI - 1)和2(PAI - 2)、组织型纤溶酶原激活物(t - PA)、尿激酶(u - PA)和D - 二聚体(D - D)进行了定量分析。然后将这些数据与炎症或感染参数,即纤维蛋白原、血管性血友病因子(vWF)、红细胞沉降率(ESR)、蛋白浓度和白细胞计数进行关联分析。胸腔积液中的D - D水平高于血浆。D - D水平与纤溶酶原激活物或纤溶酶原激活物抑制剂水平均无相关性,提示存在其他纤溶途径。结核和脓胸患者的PAI水平(PAI活性、PAI - 1抗原性、PAI - 2抗原性)和vWF水平显著高于癌症或心力衰竭患者。炎症和纤溶参数之间的回归分析表明,胸腔PAI水平与胸腔中性粒细胞计数、vWF水平和血浆纤维蛋白原水平显著相关。D - D水平与血液ESR相关。不同病因之间胸腔t - PA、u - PA和D - D水平无显著差异。癌症患者,尤其是淋巴瘤患者的胸腔t - PA和u - PA值最高。充血性心力衰竭继发胸腔积液患者的血浆t - PA水平较高,但这一差异未达到统计学意义。(摘要截选至250词)

相似文献

1
Fibrinolytic and inflammatory processes in pleural effusions.胸腔积液中的纤溶和炎症过程。
Eur Respir J. 1995 Aug;8(8):1352-6. doi: 10.1183/09031936.95.08081352.
2
Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.感染性胸腔积液中炎症介质与纤溶系统之间的关联
Clin Sci (Lond). 2003 Nov;105(5):601-7. doi: 10.1042/CS20030115.
3
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.恶性胸膜间皮瘤患者血浆和胸腔积液中的纤溶系统
Thromb Res. 1996 Oct 15;84(2):121-8. doi: 10.1016/0049-3848(96)00167-3.
4
Blood fibrinolysis and the response to desmopressin in glomerulonephritis.肾小球肾炎中的血液纤维蛋白溶解及对去氨加压素的反应
Thromb Haemost. 1994 Jan;71(1):19-25.
5
Fibrinolytic system during long-distance running in IDDM patients and in healthy subjects.胰岛素依赖型糖尿病患者和健康受试者长跑过程中的纤溶系统。
Diabetes Care. 1992 Aug;15(8):991-6. doi: 10.2337/diacare.15.8.991.
6
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.人类肿瘤坏死因子输注期间纤维蛋白溶解的进展。组织型纤溶酶原激活物、1型纤溶酶原激活物抑制剂和纤维蛋白(原)降解产物同时增加。
Blood. 1990 Dec 1;76(11):2284-9.
7
Evidence for an active fibrinolytic system in normal human bone marrow.正常人类骨髓中存在活跃纤维蛋白溶解系统的证据。
Br J Haematol. 1996 Apr;93(1):170-6. doi: 10.1046/j.1365-2141.1996.442985.x.
8
Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.根据血浆血栓调节蛋白、蛋白S、纤溶酶原激活物抑制剂-1、组织型纤溶酶原激活物和血管性血友病因子水平判断,原发性血小板增多症患者的血小板过度活化与血管内皮细胞损伤无关。
Thromb Haemost. 1993 Nov 15;70(5):736-42.
9
Pathways of fibrin turnover of human pleural mesothelial cells in vitro.人胸膜间皮细胞体外纤维蛋白周转途径。
Am J Respir Cell Mol Biol. 1992 Oct;7(4):414-26. doi: 10.1165/ajrcmb/7.4.414.
10
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.卵巢癌患者血液和肿瘤液中的纤溶酶原激活剂及纤溶酶原激活剂抑制剂
Eur J Cancer. 1994;30A(9):1302-9. doi: 10.1016/0959-8049(94)90178-3.

引用本文的文献

1
Anti-Thrombotic Activity of 3-Deoxysappanchalcone via Inhibiting Platelet Aggregation and Thrombin (FIIa)/Activated Factor X (FXa) Activity.3-脱氧番荔枝查耳酮通过抑制血小板聚集和凝血酶(FIIa)/活化因子X(FXa)活性发挥抗血栓形成作用。
Molecules. 2025 Jun 13;30(12):2580. doi: 10.3390/molecules30122580.
2
Targeting the PAI-1 Mechanism with a Small Peptide Increases the Efficacy of Alteplase in a Rabbit Model of Chronic Empyema.用一种小肽靶向纤溶酶原激活物抑制剂-1机制可提高阿替普酶在兔慢性脓胸模型中的疗效。
Pharmaceutics. 2023 May 14;15(5):1498. doi: 10.3390/pharmaceutics15051498.
3
Reduced risk of arterial thromboembolism in cats with pleural effusion due to congestive heart failure.
充血性心力衰竭导致胸腔积液的猫发生动脉血栓栓塞的风险降低。
J Feline Med Surg. 2022 Aug;24(8):e142-e152. doi: 10.1177/1098612X221094663. Epub 2022 May 13.
4
Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.纤溶酶原激活物抑制剂-1 机制的精准靶向提高脓胸纤维蛋白溶解治疗的疗效。
Physiol Rep. 2021 May;9(9):e14861. doi: 10.14814/phy2.14861.
5
The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review.尿激酶型纤溶酶原激活物及其受体对胸膜和实质肺损伤与修复的作用:一个叙述性综述。
Int J Mol Sci. 2021 Feb 1;22(3):1437. doi: 10.3390/ijms22031437.
6
PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax.恶性胸腔积液、类肺炎性胸腔积液和心源性胸腔积液中 PAI-1 水平的差异。
Medicina (Kaunas). 2019 Sep 4;55(9):567. doi: 10.3390/medicina55090567.
7
Comparative Analysis of Mean Pleural Fluid D-dimer Level in Malignant and Non-Malignant Pleural Effusion Patients.恶性和非恶性胸腔积液患者胸腔积液平均D-二聚体水平的比较分析
Tanaffos. 2019 Jan;18(1):47-51.
8
Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy.接受胸腔镜检查的非小细胞肺癌伴胸腔积液患者的生存预测因素
Thorac Cancer. 2019 Jun;10(6):1412-1418. doi: 10.1111/1759-7714.13086. Epub 2019 May 15.
9
Biomarkers of endothelial activation/dysfunction distinguish sub-groups of Ugandan patients with sepsis and differing mortality risks.内皮细胞激活/功能障碍的生物标志物可区分乌干达败血症患者亚组,并具有不同的死亡风险。
JCI Insight. 2019 Apr 23;5(10):127623. doi: 10.1172/jci.insight.127623.
10
Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema.LTI-01(单链尿激酶)胸腔内给药治疗复杂性类肺炎性胸腔积液或脓胸的 1 期临床试验。
JCI Insight. 2019 Apr 18;5(10):127470. doi: 10.1172/jci.insight.127470.